HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ehrenberg, H. M. Articles by Mercer, B. M. Search for Related Content PubMed PubMed Citation Articles by Ehrenberg, H. M. Articles by Mercer, B. M. Related Collections Hypertension and PIH

Abbreviated Postpartum Magnesium Sulfate Therapy for Women With Mild Preeclampsia

A Randomized Controlled Trial

From the ¹Department of Reproductive Biology, Case Western Reserve University School of Medicine, and ²Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, Ohio.

OBJECTIVE: To determine whether women receiving 12-hour and 24-hour postpartum magnesium sulfate (MgSO₄) therapy for mild preeclampsia have differing clinical courses.

METHODS: Consenting women with suspected mild preeclampsia were randomly assigned to12 hours or 24 hours of MgSO₄ postpartum therapy. Treatment was continued after the assigned time period if there was evidence of severe preeclampsia. The frequency of progression to severe disease and other outcomes were compared between study groups using the Fisher exact, ², and Student t tests where appropriate.

RESULTS: Between January 2001 and August 2004, 200 women were enrolled. The 12-hour and 24-hour groups were similar in age, parity, delivered gestational age, anesthesia, and mode of delivery, as well as for proteinuria and blood pressure. In the 12-hour group, MgSO₄ treatment was extended in seven women (6.9%) for progression to severe disease versus one (1.1%) in the 24-hour group (P=.07). Women who developed severe disease had higher blood pressures at the first prenatal visit (140/78 versus 122/69, P.02 for systolic and diastolic pressures), at the time of randomization (152/88 versus 135/78, P.03 for systolic and diastolic pressures), and were more likely to have insulin-requiring diabetes (27.3% versus 4.4%, P=.03). No 12-hour patients required treatment beyond 24 hours postpartum. There were no seizures, MgSO₄ toxicity, or intolerance in either group.

CONCLUSION: Twelve hours of postpartum MgSO₄ therapy for mild preeclampsia is associated with infrequent disease progression and a clinical course similar to that with 24-hour therapy. Patients with chronic hypertension and insulin-requiring diabetes are at risk for progression to severe disease postpartum.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00344058

LEVEL OF EVIDENCE: I

This article has been cited by other articles:

				J. R. Scott Preventing eclampsia: magnesium sulfate regimens revisited. Obstet. Gynecol., October 1, 2006; 108(4): 824 - 825. [Full Text] [PDF]